RBC Capital analyst Brian Abrahams keeps a Sector Perform rating and $816 price target on Regeneron ahead of the company’s high-dose Eylea PDUFA today. While there are some risks/uncertainties, based on prior results and class trends, the 2-year data should continue to look competitive and enable preservation of about 2/3rd of its market share, or about $4B in estimated 2026 U.S. sales, even in the face of biosimilar entry necessary to avoid IRA discounting, the analyst tells investors in a research note. RBC adds that the firm remains “comfortable holding shares” into the readout, though still believes that consensus out-year Eylea numbers may already reflect an optimistic case for high-dose Eylea conversion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron Stock (NASDAQ:REGN) Sinks; FDA Snubs Higher-Dose Eye Drug
- FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
- Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
- Regeneron named ‘Catalyst Driven Idea’ at Morgan Stanley
- Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma